转移性结直肠癌的个性化治疗:基于生物标志物的使用
Francesco Sullo1, Chiara Gallio1, Laura Matteucci1
1Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
精准医学通过向RAS和BRAF等分子变异来优化转移性结直肠癌 (mCRC) 的治疗. 液体活检有助于监测治疗反应和检测耐药性,以改善患者的治疗结果.
科学领域:
- 癌症学
- 分子生物学
- 遗传学
背景情况:
- 转移性结肠直肠癌 (mCRC) 在全球面临重大死亡挑战.
- 尽管治疗方面取得了进展,但长期生存率仍然有限.
- 在mCRC的分子异质性需要个性化治疗策略.
研究的目的:
- 在mCRC中审查当前和新兴的分子目标.
- 讨论各种生物标志物和罕见变化的临床意义.
- 探索液体活检在管理mCRC中的作用.
主要方法:
- 对临床试验,指导方针和转化研究的综合文献审查.
- 分子目标的分析,包括RAS,BRAF,HER2和微卫星的不稳定性.
- 评估瘤侧向性,EGFR连接体表达和罕见的融合 (NTRK,RET,ALK).
主要成果:
- 克拉斯G12C抑制剂和针对HER2的疗法具有不断变化的作用.
- 液体活检,特别是ctDNA,对于监测,再检测和抗药性检测至关重要.
- 瘤侧面性和特定的分子变化影响治疗选择.
结论:
- 在mCRC中可以通过分子分析实现个性化治疗.
- 克服耐药性,标准化测试和确保获取是关键的挑战.
- 将创新药物与实时分子监测相结合,可以改善mCRC的管理.
更多相关视频
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Treatment Resistant Cancers
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
